Drug Trial Radar · NCT01594970
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
Last checked: Nov 19, 2026Latest source record: Jan 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Mar 2012
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 9, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
Conditions
- Glaucoma, Open-Angle
- Ocular Hypertension
Interventions
Bimatoprost 0.01%Drug
1 drop in the affected eye(s), administered in the evening for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severity of Ocular Hyperemia in the Study Eye on a 5-Point ScaleTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.